GlassScriptPhysician profile
Paresh P Kamat
NPI 1740518612
$7,608.99
in general payments reported to CMS, 2019-2025
36 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $991 · 2021: $960 · 2022: $961 · 2023: $1,202 · 2024: $1,098 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,628.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $931.14 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $823.83 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $543.96 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Scientific Affairs, LLC | $359.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $325.26 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $218.76 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $213.67 | 2020-2024 | Dificid |
| Madrigal Pharmaceuticals | $212.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $127.47 | 2019-2024 | |
| Pfizer INC. | $100.09 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $95.48 | 2020-2023 | |
| Gilead Sciences, INC. | $95.46 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $94.22 | 2019-2020 | |
| Vivus LLC | $87.92 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $87.26 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $84.30 | 2023-2025 | Ibsrela |
| Allergan, INC. | $77.98 | 2019-2020 | |
| Boston Scientific Corporation | $62.75 | 2022-2023 | Compliance Endokit |
| Daiichi Sankyo INC. | $48.93 | 2022-2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $46.00 | 2025 | Iqirvo |
| Organon LLC | $39.58 | 2023-2024 | Hadlima, Renflexis |
| Genzyme Corporation | $35.98 | 2024 | |
| Braintree Laboratories, INC. | $30.79 | 2021 | |
| Qol Medical, LLC | $28.94 | 2024 | Sucraid |
| Ferring Pharmaceuticals INC. | $25.58 | 2024 | Rebyota |
| Redhill Biopharma INC. | $23.81 | 2020 | |
| Shire North American Group INC | $20.92 | 2019 | |
| Aimmune Therapeutics, INC. | $19.80 | 2025 | Zenpep |
| Biocon Biologics INC | $19.74 | 2024 | Hulio |
| Tempus Ai, INC | $19.67 | 2024 | |
| Celgene Corporation | $18.53 | 2024 | Zeposia |
| Amag Pharmaceuticals, INC. | $17.85 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2024 | Cyltezo |
| Olympus America INC. | $15.60 | 2025 | Endoclot Phs |
| Alfasigma USA, INC. | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paresh Kamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.